2026 Access to Medicine Index

Access to life-saving medicines should never depend on where you live

Learn why access falls short

News

Read the latest at the Foundation

Pharmaceutical companies are showing what’s possible on access to medicine, but must go further to deliver impact at scale

2026 Index Methodology zeroes in on scalable actions capable of delivering lasting impact for more people

Research hub

Read the key findings from the 2026 Access to Medicine Index

Companies step up access planning for pipeline products, but progress lags for non-communicable diseases

10 November 2026

Promising pockets of progress emerge in cancer access, but the overall picture remains uneven

10 November 2026

Inclusive business models: Momentum in expanding reach and strengthening long-term foundations, yet visibility into impact remains limited

10 November 2026

2026 Index ranking | How companies compare

Novartis again holds the number one spot, followed by GSK in second, while AstraZeneca has risen to third.

Events and engagements

Sharing our insights to help drive change

Panel discussion

Margo Warren to attend second annual AI in Health Summit

04 November 2026

Steffi Van Uytfanghe to present insights on medical oxygen access gaps at 2026 Gasworld’s Global Industrial Gas Conference

02 December 2026

Foundation to host live webinar on key findings of the 2026 Access to Medicine Index

26 January 2027

Featured Launch

UBS and Neuberger Berman to co-host investor launch events for the tenth Access to Medicine Index

10 November 2026

Access insights

Read our analyses of critical developments in the pharmaceutical industry

Gilead to extend access to lenacapavir and broaden its voluntary licences to include a new once-yearly formulation

21 September 2026

Turning momentum into vaccine manufacturing capacity in Africa